• caenes

New Pectus Excavatum surgery with Pectus Up at the Infanta Luisa Hospital in Seville

With this new surgery, there are now three Pectus Up implantations performed in this hospital of the Quirónsalud group in the andalousian capital.

Last June, the third Pectus Excavatum surgery with the Pectus Up implant, developed by Ventura Medical Technologies, took place at the Infanta Luisa Hospital in Seville.

The surgery was performed by Dr. Miguel Congregado and Dr. Fernando Cózar, two surgeons who have placed their full trust in the Pectus Up for the treatment of Pectus Excavatum.

Dr. Congregado is Head of the Thoracic Surgery Service at the Quirónsalud Infanta Luisa Hospital in Seville, as well as the person responsible for quality and teaching at the Virgen Macarena University Hospital. He is also Coordinator of the Institutional Relations and Professional Affairs Committee of the Spanish Society of Thoracic Surgery (SECT) and a member of several associations such as the European Society of Thoracic Surgeons (ESTS) or the Society of Thoracic Surgeons (STS) among others.

In turn, Dr. Cózar is an area specialist in Thoracic Surgery at the University Hospital Virgen Macarena and performs surgeries in other Sevillian hospitals, such as the Hospital Fátima, the Hospital Vithas-Nisa or the Hospital Santa Ángela Viamed de la Cruz. He is also a member of the European Society of Thoracic Surgeons (ESTS) and the Spanish Association of Surgeons (AEC).

The patient, a 15-year-old male, had a symmetrical Pectus Excavatum, with a slight sternal rotation and a Haller index of 3.61. The depth to be raised was 2.7 centimeters and the result was fully satisfactory.

“The before and after is amazing, doctor. We are very happy”, were the words of the young man’s parents, who is recovering with no complications at home.

The Pectus Up is thus consolidated as a great alternative for the treatment of Pectus Excavatum. At the time, it is marketed in different European countries (France, United Kingdom, Italy, Greece, Portugal and Slovakia), and also in Latin America (Mexico, Colombia, Chile, Peru and Costa Rica). Currently, it is in the process of obtaining the FDA registration for its commercialization in the United States.